Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

Javier Pinilla-Ibarz, Jorge Cortes, Michael J. Mauro

Research output: Contribution to journalReview article

Abstract

Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region-Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long-term imatinib therapy; however, the availability of the second-generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long-term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML-specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients.

Original languageEnglish (US)
Pages (from-to)688-697
Number of pages10
JournalCancer
Volume117
Issue number4
DOIs
StatePublished - Feb 15 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Quality of Life
Therapeutics
Abelson murine leukemia virus
Equipment and Supplies
Imatinib Mesylate

Keywords

  • dasatinib
  • imatinib
  • intolerance
  • nilotinib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. / Pinilla-Ibarz, Javier; Cortes, Jorge; Mauro, Michael J.

In: Cancer, Vol. 117, No. 4, 15.02.2011, p. 688-697.

Research output: Contribution to journalReview article

Pinilla-Ibarz, Javier ; Cortes, Jorge ; Mauro, Michael J. / Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. In: Cancer. 2011 ; Vol. 117, No. 4. pp. 688-697.
@article{b107921ccf034e4fb2e1dff04b5a6719,
title = "Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia",
abstract = "Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region-Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long-term imatinib therapy; however, the availability of the second-generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long-term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML-specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients.",
keywords = "dasatinib, imatinib, intolerance, nilotinib, tyrosine kinase inhibitor",
author = "Javier Pinilla-Ibarz and Jorge Cortes and Mauro, {Michael J.}",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/cncr.25648",
language = "English (US)",
volume = "117",
pages = "688--697",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

AU - Pinilla-Ibarz, Javier

AU - Cortes, Jorge

AU - Mauro, Michael J.

PY - 2011/2/15

Y1 - 2011/2/15

N2 - Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region-Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long-term imatinib therapy; however, the availability of the second-generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long-term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML-specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients.

AB - Tyrosine kinase inhibitor (TKI) treatment targeting breakpoint cluster region-Abelson murine leukemia virus, the cause of chronic myeloid leukemia (CML), has revolutionized therapy for patients with this disease. The majority of patients with CML maintain favorable responses with long-term imatinib therapy; however, the availability of the second-generation TKIs nilotinib and dasatinib limits the need for patients intolerant to imatinib to continue with therapy. Unfortunately, there is currently no standard definition of intolerance to imatinib. Common Toxicity Criteria for grading adverse events, designed to identify acute toxicities, are often used to determine intolerance. However, because CML therapies are long-term, patient quality of life may provide a better measure of true intolerance. Several general methods of quantifying patient quality of life are in use for patients with CML, and a CML-specific variant of the M. D. Anderson Symptom Inventory is in development. An appropriate and consistent definition of intolerance will provide clinicians with an algorithm for managing their patients with severe or chronic adverse events during treatment with imatinib. As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients.

KW - dasatinib

KW - imatinib

KW - intolerance

KW - nilotinib

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=79551692491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551692491&partnerID=8YFLogxK

U2 - 10.1002/cncr.25648

DO - 10.1002/cncr.25648

M3 - Review article

C2 - 20922786

AN - SCOPUS:79551692491

VL - 117

SP - 688

EP - 697

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -